MAXONA Pharmaceuticals is a clinical-stage company committed to leveraging an ex-U.S. marketed non-Opioid, non-NSAID, non-CBD analgesic as a New Molecular Entity for the treatment of acute and chronic pain in the United States.
While the U.S. continues to experience an opioid abuse epidemic, exacerbated by the COVID pandemic, there has been very limited innovation to address the needs of millions of Americans suffering from acute and chronic pain. Hence, there is a significant need for safe and efficacious alternative analgesics. MAXONA Pharmaceuticals aims to fundamentally address this short-coming by developing it’s lead molecule MAX-001.
News & Events:
January 2021 – U.S. Patent Office indicated that U.S. Patent Application Serial No. 16/912,324 contained allowable subject matter. This application is part of MAXONA’s patent strategy for MAX-001 and once issued should provide patent protection until September 2037.
April 2020 – U.S. Patent Office indicated that U.S. Patent Application Serial No. 16/124,957 contained allowable subject matter.
January 2020 – Shawn Fatholahi, President & CEO of MAXONA Pharmaceuticals, presented a company update at the Biotech Showcase investors conference, on Wednesday January 15th, 2020 at 11:00 AM (PST) in the Franciscan A ballroom of the Hilton San Francisco Union Square Hotel – San Francisco, CA.
January 2020 – MAXONA Pharmaceuticals was in attendance at the J.P.Morgan Healthcare Conference January 12-16, 2020 – San Francisco, CA
June 2019 – MAXONA Pharmaceuticals was in attendance at the RESI Conference in conjunction with BIO 2019 Annual Conference in Philadelphia, PA.
April 2019 – “FDA pre-IND feedback provides clarity on MAX-001 development plans and a roadmap to NDA filing”
November 2017 – The U.S. Patent Office indicated that U.S. Patent Application Serial No. 15/699,856 contained allowable subject matter.